didecanoylphosphatidylcholine: permeation enhancer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
1,2-dicapryl-sn-glycero-3-phosphocholine : A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at positions 1 and 2 are specified as capryl (decanoyl). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 16219892 |
| CHEBI ID | 78226 |
| SCHEMBL ID | 236092 |
| MeSH ID | M0064180 |
| Synonym |
|---|
| 66bxc7tk3j , |
| unii-66bxc7tk3j |
| l-dicapryllecithin |
| didecanoylglycerophosphocholine |
| l-didecanoyllecithin |
| didecanoyllecithin |
| didecanoylphosphatidylcholine |
| LMGP01010380 |
| l-alpha-didecanoylphosphatidylcholine |
| decanoin, 1,2-di-, dihydrogen phosphate, monoester with choline hydroxide inner salt, l- |
| choline, hydroxide, dihydrogen phosphate, inner salt, ester with 1,2-didecanoin, l- |
| didecanoyl-l-alpha-glycerophosphorylcholine |
| pc(10:0/10:0) |
| 1,2-didecanoyl-sn-glycero-3-phosphocholine |
| 1,2-didecanoyl-sn-glycero-3-phosphocholine, >=99% (tlc) |
| 3436-44-0 |
| 1,2-dicapryl-sn-glycero-3-phosphocholine |
| didecanoyl-l-alpha-phosphatidylcholine |
| SCHEMBL236092 |
| 3,5,9-trioxa-4-phosphanonadecan-1-aminium, 4-hydroxy-n,n,n-trimethyl-10-oxo-7-((1-oxodecyl)oxy)-, inner salt, 4-oxide, (7r)- |
| didecanoyl-l-.alpha.-phosphatidylcholine |
| ddpc, r- |
| 10:0 pc, r- |
| ddpc, l- |
| 1,2-didecanoyl-phosphatidylcholine, r- |
| l-didecanoylphosphatidylcholine |
| dic10:0 pc |
| dcpc, l |
| (2r)-2,3-bis(decanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate |
| 1,2-dicaprinyl-sn-glycero-3-phosphocholine betaine |
| CHEBI:78226 |
| AKOS024418776 |
| 1,2-bis(o-decanoyl)-sn-glyceryl-3-phosphorylcholine |
| MLKLDGSYMHFAOC-AREMUKBSSA-N |
| HMS3650D05 |
| 3,5,9-trioxa-4-phosphanonadecan-1-aminium, 4-hydroxy-n,n,n-trimethyl-10-oxo-7-[(1-oxodecyl)oxy]-, inner salt, 4-oxide, (r)- |
| (r)-2,3-bis(decanoyloxy)propyl (2-(trimethylammonio)ethyl) phosphate |
| (2-{[(2r)-2,3-bis(decanoyloxy)propyl phosphonato]oxy}ethyl)trimethylazanium |
| AS-65391 |
| pc(20:0) |
| 1,2-didecanoyl-sn-glycero-3-phos-phocholine |
| 10:0 pc, 1,2-didecanoyl-sn-glycero-3-phosphocholine, powder |
| Q27147690 |
| [(2r)-2,3-di(decanoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate |
| A12438 |
| 1,2-didecanoyl-sn-glycero-3-phosphocholi |
| (r)-2,3-bis(decanoyloxy)propyl(2-(trimethylammonio)ethyl)phosphate |
| PD019631 |
| BP-26297 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Pharmacokinetic testing in rats confirmed the improved drug bioavailability and demonstrated an in vitro-in vivo correlation." | ( In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo. Brandt, GC; Costantino, HR; Foerder, CA; Leonard, AK; Quay, SC; Sileno, AP, 2007) | 0.34 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " In vivo studies in rats compared pharmacokinetic (PK) profiles of different formulations dosed intranasally." | ( In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo. Brandt, GC; Costantino, HR; Foerder, CA; Leonard, AK; Quay, SC; Sileno, AP, 2007) | 0.34 |
| Class | Description |
|---|---|
| 1,2-diacyl-sn-glycero-3-phosphocholine | The conjugate base of a 1,2-diacyl-sn-glycero-3-phosphocholine compound formed by deprotonation of the phosphate OH group. |
| decanoate ester | A fatty acid ester resulting from the formal condensation of the carboxy group of decanoic acid (capric acid) with the hydroxy group of an alcohol or phenol. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (87.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.16) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||